Asta Juzeniene
Overview
Explore the profile of Asta Juzeniene including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
2591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song L, Kostas M, Laerdahl J, Skalova M, Janska T, Juzeniene A, et al.
ACS Omega
. 2025 Feb;
10(6):5730-5743.
PMID: 39989790
The fibroblast growth factor receptor family members, FGFR1-4, are frequently overexpressed in various solid tumors, including breast cancer and sarcomas. This overexpression highlights the potential of the family of FGFRs...
2.
Lindland K, Malenge M, Li R, Wouters R, Bonsdorff T, Juzeniene A, et al.
Sci Rep
. 2024 Oct;
14(1):25941.
PMID: 39472474
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of...
3.
Sioud M, Juzeniene A, Saeboe-Larssen S
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932353
Therapeutic modified mRNAs are being developed for a broad range of human diseases. However, the impact of potential miscoding of modified mRNAs on self-tolerance remains unknown. Additionally, more studies are...
4.
Kvassheim M, Tornes A, Juzeniene A, Stokke C, Revheim M
EJNMMI Phys
. 2023 Aug;
10(1):47.
PMID: 37603123
Introduction: Pb is a promising radionuclide for targeted alpha therapy. Here, the feasibility of visualising the tumour uptake and biodistribution of Pb-NG001 in mice with a clinical SPECT/CT scanner was...
5.
Mensali N, Koksal H, Joaquina S, Wernhoff P, Casey N, Romecin P, et al.
Nat Commun
. 2023 Jun;
14(1):3375.
PMID: 37291203
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other...
6.
Bruland O, Larsen R, Baum R, Juzeniene A
Front Med (Lausanne)
. 2023 Mar;
10:1165747.
PMID: 36960341
No abstract available.
7.
Juzeniene A, Stenberg V, Bruland O, Revheim M, Larsen R
Front Med (Lausanne)
. 2023 Feb;
9:1051825.
PMID: 36733936
Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha-emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need. The...
8.
Tornes A, Stenberg V, Larsen R, Bruland O, Revheim M, Juzeniene A
Front Med (Lausanne)
. 2022 Dec;
9:1058863.
PMID: 36507500
Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an epitope...
9.
Use of antihypertensive drugs and risk of cutaneous melanoma: a nationwide nested case-control study
Ghiasvand R, Berge L, Andreassen B, Stenehjem J, Heir T, Karlstad O, et al.
Int J Epidemiol
. 2022 Nov;
52(3):887-898.
PMID: 36413027
Background: Most antihypertensives can induce dermal photosensitivity, which may increase melanoma risk. However, corroborating evidence is limited. We examined the associations between use of antihypertensives and melanoma risk. Methods: A...
10.
Stenberg V, Tornes A, Nilsen H, Revheim M, Bruland O, Larsen R, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681766
This study aimed to determine the influence of cellular PSMA expression, radioligand binding and internalization, and repeated administrations on the therapeutic effects of the PSMA-targeting radioligand Pb-NG001. Cellular binding and...